Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Depiction of a blood clot forming inside a blood vessel. 3D illustration
About Us
op2lysis

Op2lysis is a biotechnology company that researches and develops innovative medicines whose purpose is to lyse hematoma and blood clot formed during thrombosis in the brain.

Products of our portfolio are based on our NANOp2Lysis® technology and on our innovative thrombolytic agent, OptPA.

The Technology
NANOp2Lysis®

The NANOp2Lysis® platform is a disruptive technology with several potential applications to address unmet medical needs through progress in drug delivery. Our vision is that this technology will unveil the full efficacy of thrombolytic agents to better lyse hematoma and blood clots.

OptPA

Optimized tPA (OptPA) is a new generation of thrombolytic agent engineered from the goldstandard tPA (tissue plasminogen activator) and optimized to ensure safer action.

  • A novel thrombolytic agent
  • An improved safety profile
  • Reduce the pro-bleeding risk
  • Specifically optimised to avoid neurotoxicity
7
PIPELINE
O2L-001

O2L-001 is an innovative easy, effective, and safe medicine for hemorrhagic stroke, an unmet medical need.

O2L-001 is the first product from the NANOp2Lysis® platform. O2L-001 is a therapeutic solution to treat patient suffering of hemorrhagic stroke, an unmet medical need.
O2L-001 ensures rapid and safe removal of the hematoma that has formed in the brain following the bleeding event leading to the reduction of the disability and mortality associated with the acute phase of hemorrhagic strokes.

servicebox
Extended-release
technology for reduced dosing frequency
servicebox
Easy to use,
safe and
effective
INDICATIONS
Hemorrhagic stroke

The challenge of the Stroke Action Plan for Europe 2018-2030, to reduce the burden of stroke and address its long-term consequences, drives Op2Lysis towards the development of innovative products.

Meet With Us
FOR MORE INFORMATION